Father and Child

 

Our licensor Biofrontera Bioscience conducts extensive research to optimize the market potential of Ameluz® and BF-RhodoLED®. That research includes both late-stage and early development product candidates that target specific treatment needs in the dermatology market.

Product Indication / comments Clinical Phase Submission Approval Status
I II III
BF-200 ALA AK: Pharmacokinetics study Completed
BF-200 ALA AK: Safety study for use of 3 tubes Study ongoing
RhodoLED®XL Illumination of larger body regions FDA approval in October 2021
BF-200 ALA Superficial basal cell carcinoma Phase III ongoing
BF-200 ALA Moderate to severe acne Phase II ongoing
BF-200 ALA AK: Face and scalp with pain-reducing illumination protocol Phase III in preparation
BF-200 ALA AK: Trunk & extremities Phase III in preparation
BF-200 ALA Squamous cell carcinoma in situ Phase III in preparation

 

Link to clinical trial page -> Clinical trials - Biofrontera

Biofrontera continues to deepen its expertise in dermatology and contribute to the advancement of treatment options that enable dermatology healthcare professionals to help improve the lives of their patients.
Most notably, Biofrontera’s research and development activities over the past decade have been improving treatment possibilities with photodynamic therapy (PDT) to make PDT accessible to more individuals.